Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P11 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Trials in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P11.01 - Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
00:00 - 00:00 | Presenter: Edward B Garon
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
Loading... -
+
OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
19:15 - 19:25 | Presenter: D. Ross Camidge
- Abstract
Loading...